Wuxi AppTec (603259) delivered a financial performance in 2025 that could be described as explosive: both revenue and net profit reached new highs since its listing, and the total annual dividend payout also set a new record, with the stock price doubling at one point during the year.
Against the backdrop of cyclical adjustments facing the entire pharmaceutical outsourcing industry, this sector leader, whose vision is to "make difficult drugs and diseases easy to tackle," appears to be demonstrating its resilience through data.
However, behind the impressive results lie several noteworthy details. A significant portion of profit, 5.9 billion yuan, came from non-recurring gains. The controlling shareholders cashed out over 5.3 billion yuan again while the stock price was high. Research and development investment has decreased for four consecutive years, and the employee headcount has been reduced by over 10,000 in three years.
Is this record-breaking financial report the starting point for a new phase of growth, or merely an annotation of a cyclical peak?
**Profit Doubling Contains Significant "One-Time" Elements** Data shows that in 2025, Wuxi AppTec achieved operating revenue of 45.456 billion yuan, a year-on-year increase of 15.84%. Net profit attributable to shareholders of the listed company reached 19.151 billion yuan, a substantial increase of 102.65%. Both of these key metrics set new records since the company's listing in 2018.
Furthermore, the company proposed a generous dividend plan – a cash dividend of 15.7927 yuan per share (before tax), totaling approximately 4.712 billion yuan. Combined with the 1.033 billion yuan dividend distributed mid-year, the total dividend payout for 2025 reached 5.745 billion yuan, also a record high since listing.
A closer look at the profit structure reveals certain special factors behind this "explosive" performance. The company's net profit after deducting non-recurring gains and losses was 13.241 billion yuan, a year-on-year increase of 32.56%. While this growth rate is still considerable, it is far less than the doubling seen in the net profit attributable to shareholders.
The difference – approximately 5.91 billion yuan – primarily originated from gains on the sale of part of the company's equity in the associate WuXi XDC Cayman Inc. and the divestiture of certain businesses. In other words, this nearly 6-billion-yuan profit constitutes a "one-time" inflow, not a result of sustained contributions from core operations.
Wuxi AppTec primarily provides integrated, end-to-end new drug research, development, and manufacturing services for the global pharmaceutical and life sciences industry, with a business network covering Asia, Europe, and North America. Its core business model is "CRDMO" (Contract Research, Development, and Manufacturing), encompassing chemical business, testing business, biology business, and other segments, positioning it as a typical "pick-and-shovel" provider in the industry.
From a revenue structure perspective, the chemical business remains the primary engine of growth. In 2025, revenue from this segment grew 25.52% year-on-year. The TIDES business (comprising oligonucleotide and peptide) performed particularly well, generating revenue of 11.37 billion yuan, a significant 96% increase. As of the end of 2025, the TIDES order backlog grew 20.2% year-on-year. The small molecule D&M business revenue reached 19.92 billion yuan, an 11.4% increase, with 839 new molecules added during the year, bringing the total pipeline molecules to 3,452.
As the proportion of high-value-added business increases, the company's overall profitability has also risen. In 2025, Wuxi AppTec's comprehensive gross profit margin was 47.64%, an increase of 6.16 percentage points year-on-year. The gross profit margin for the chemical business reached 51.89%, up 5.5 percentage points.
The company's order backlog also continued to climb, reaching 58 billion yuan by the end of 2025, a 28.8% year-on-year increase. To meet future delivery demands, the company is continuously expanding production capacity and has provided clear performance guidance: it expects overall revenue for 2026 to reach between 51.3 billion and 53 billion yuan, representing growth of 18% to 22%. Judging from the alignment of orders and capacity, the visibility for the company's performance over the next two years is relatively high.
**Three Major Concerns Emerge** On the flip side of rapid growth, some potential risks associated with Wuxi AppTec warrant attention.
First, dependence on overseas markets has deepened further. In 2025, revenue from overseas clients rose to 83.5% of the total. Revenue from U.S. clients contributed 31.25 billion yuan, a 34.3% year-on-year increase, while revenue from European and Chinese markets declined by 4.0% and 3.5%, respectively. Against the macro backdrop of long-term Sino-U.S. strategic competition, whether this high reliance on a single market will pose future operational risks remains to be seen.
Second, as the business expands, operational efficiency has declined, putting pressure on capital. The company's inventory scale increased from 4.736 billion yuan in 2023 to 8.993 billion yuan in 2025. The inventory turnover ratio decreased from 4.56 times per year to 3.31 times per year, and the turnover days extended from 78.93 days to 108.85 days.
Simultaneously, notes payable and accounts payable increased from 1.645 billion yuan in 2024 to 2.45 billion yuan. Short-term borrowings also surged from 1.243 billion yuan in 2024 to 5.986 billion yuan in 2025.
To alleviate pressure, the company reduced general and administrative expenses from 2.879 billion yuan to 2.661 billion yuan, and also cut R&D expenses from 1.239 billion yuan to 1.119 billion yuan. Additionally, it bolstered liquidity through capital market activities – completing an H-share placement in 2025 at HKD 104.27 per share, raising net proceeds of approximately HKD 7.647 billion, with 90% planned for global expansion and capacity building.
Third, R&D investment has been shrinking for four consecutive years. In 2022, R&D expenses were 1.614 billion yuan, accounting for 4.1% of revenue. By 2025, R&D expenses had decreased to 1.119 billion yuan, representing only 2.46% of revenue – a cumulative reduction of approximately 30% over four years.
Concurrently, the number of R&D personnel decreased from 36,700 in 2022 to 26,000 in 2025. The total employee headcount also dropped from 44,400 to 33,800.
The company's periodic reports provide limited commentary on this change, merely stating it results from efficiency improvements and operational optimization driven by the "CRDMO" business model. However, in a pharmaceutical R&D services industry highly dependent on technology and talent investment, does the continuous reduction in R&D "costs" affect the company's long-term competitiveness? Does it imply a leading company's anticipation of an industry cycle? These have become underlying concerns for the market.
**Controlling Shareholders Cash Out 17 Billion Yuan in Five Years** For investors, while improving performance is certainly welcome, the divestment actions by related parties at high stock price levels are hard to ignore.
Along with the continuous release of operating performance, Wuxi AppTec's stock price performed strongly in 2025, rising approximately 70% for the year, with a maximum increase exceeding 100% during the period, mainly concentrated between April and August.
However, just as the stock price was at a relatively high level, shareholders controlled by the actual controller disclosed a reduction plan in October 2025, proposing to sell up to 59.6751 million shares within three months, representing no more than 2% of the total share capital.
According to the reduction results disclosed on January 7, 2026, this plan was executed at the maximum allowable level – approximately 29.83 million shares were sold each through centralized bidding and block trades. The selling price range was between 84.66 yuan and 95.07 yuan per share, resulting in an estimated cash-out amount of up to 5.343 billion yuan.
The announcement indicated that the source of the reduced shares was primarily pre-IPO holdings, with the buyers mostly being well-known international investors.
The divestment by the controlling shareholders also triggered a chain reaction. Looking at changes among the top ten shareholders, the second-largest shareholder, Hong Kong Securities Clearing Company Limited, reduced its holding by 37.3681 million shares. The China Construction Bank - E Fund CSI 300 Healthcare ETF also reduced its holding by 13.1745 million shares.
Under sustained selling pressure, Wuxi AppTec's stock price entered a consolidation phase starting September 2025, subsequently falling approximately 14% over the next four months, leaving many investors sighing.
This is not the first large-scale cash-out by the controlling parties. Between late 2022 and 2023, the controlling parties executed multiple reductions, cashing out approximately 12 billion yuan in total. Combined with the latest round, the total cash-out amount by the controlling parties amounts to roughly 17 billion yuan in less than five years.
Record performance, a full order book, capacity expansion, and a doubling stock price – Wuxi AppTec seems to be in a "highlight moment." However, factors such as profit growth supported by non-recurring items, significant cash-outs by controlling shareholders at high prices, continuously declining R&D investment, and deepening reliance on overseas markets also raise questions about the sustainability of its growth.
The 2026 revenue target is set, and the order backlog is revealed. Amidst multiple intertwined variables, whether Wuxi AppTec can once again deliver performance exceeding expectations will ultimately be answered by time.
Comments